Benjamin F. Edwards & Company Inc. Buys 12,326 Shares of ResMed Inc. (NYSE:RMD)

Benjamin F. Edwards & Company Inc. boosted its position in ResMed Inc. (NYSE:RMD) by 46.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,069 shares of the medical equipment provider’s stock after acquiring an additional 12,326 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in ResMed were worth $7,479,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of ResMed by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 17,743,457 shares of the medical equipment provider’s stock valued at $3,052,229,000 after purchasing an additional 173,635 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in ResMed by 51.4% in the second quarter. Bank of New York Mellon Corp now owns 5,772,761 shares of the medical equipment provider’s stock worth $1,105,022,000 after buying an additional 1,959,642 shares in the last quarter. Los Angeles Capital Management LLC grew its position in ResMed by 48.3% during the second quarter. Los Angeles Capital Management LLC now owns 740,226 shares of the medical equipment provider’s stock valued at $141,694,000 after acquiring an additional 241,195 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of ResMed by 15.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 698,905 shares of the medical equipment provider’s stock worth $120,225,000 after acquiring an additional 95,689 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of ResMed by 19.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 661,717 shares of the medical equipment provider’s stock worth $126,670,000 after acquiring an additional 107,279 shares during the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

ResMed Trading Up 0.8 %

RMD opened at $244.90 on Friday. ResMed Inc. has a one year low of $132.24 and a one year high of $255.18. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.59 and a quick ratio of 1.69. The business has a 50 day simple moving average of $226.91 and a two-hundred day simple moving average of $209.22. The firm has a market capitalization of $35.98 billion, a price-to-earnings ratio of 37.62, a PEG ratio of 2.50 and a beta of 0.69.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 EPS for the quarter, beating analysts’ consensus estimates of $2.03 by $0.05. ResMed had a return on equity of 25.00% and a net margin of 21.79%. The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.22 billion. During the same quarter in the prior year, the company earned $1.60 earnings per share. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. Analysts predict that ResMed Inc. will post 8.92 EPS for the current year.

ResMed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 19th. Stockholders of record on Thursday, August 15th were given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.87%. This is a boost from ResMed’s previous quarterly dividend of $0.48. The ex-dividend date was Thursday, August 15th. ResMed’s dividend payout ratio (DPR) is currently 32.57%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Wolfe Research reaffirmed an “underperform” rating and set a $180.00 target price on shares of ResMed in a report on Wednesday. Royal Bank of Canada raised their price objective on ResMed from $204.00 to $206.00 and gave the company a “sector perform” rating in a research note on Friday, August 2nd. Needham & Company LLC reissued a “hold” rating on shares of ResMed in a research note on Wednesday. KeyCorp raised their price target on ResMed from $238.00 to $251.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, StockNews.com cut ResMed from a “buy” rating to a “hold” rating in a research note on Friday, August 30th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $199.70.

Insider Transactions at ResMed

In related news, insider Kaushik Ghoshal sold 5,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the transaction, the insider now owns 21,788 shares in the company, valued at $5,502,777.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other ResMed news, insider Kaushik Ghoshal sold 5,000 shares of ResMed stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the sale, the insider now directly owns 21,788 shares of the company’s stock, valued at approximately $5,502,777.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Brett Sandercock sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $194.35, for a total value of $194,350.00. Following the transaction, the chief financial officer now owns 90,056 shares in the company, valued at approximately $17,502,383.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 102,931 shares of company stock valued at $22,644,807. Company insiders own 1.21% of the company’s stock.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.